Fan P, Maximov P, Curpan R, Abderrahman B, Jordan V
Mol Cell Endocrinol. 2015; 418 Pt 3:245-63.
PMID: 26052034
PMC: 4760743.
DOI: 10.1016/j.mce.2015.06.004.
Jordan V, McDaniel R, Agboke F, Maximov P
Steroids. 2014; 90:3-12.
PMID: 24949934
PMC: 4192084.
DOI: 10.1016/j.steroids.2014.06.009.
Jordan V
Br J Clin Pharmacol. 2014; 79(2):254-67.
PMID: 24912921
PMC: 4309631.
DOI: 10.1111/bcp.12440.
Vasconcelos A, Nunes B, Duarte C, Mendonca V, Ribeiro J, Jorge M
Rep Pract Oncol Radiother. 2014; 18(5):251-60.
PMID: 24416561
PMC: 3863172.
DOI: 10.1016/j.rpor.2013.06.005.
Robinson D, Holmberg L, Moller H
Br J Cancer. 2008; 99(4):611-5.
PMID: 18665169
PMC: 2527835.
DOI: 10.1038/sj.bjc.6604524.
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan V, Brodie A
Steroids. 2006; 72(1):7-25.
PMID: 17169390
PMC: 2566956.
DOI: 10.1016/j.steroids.2006.10.009.
Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.
Doihara , Takashima , Kurita , Moriwaki
Breast Cancer. 1996; 3(1):25-31.
PMID: 11091550
DOI: 10.1007/BF02966959.
Gynecologic effects of tamoxifen: case reports and review of the literature.
Caputo R, Copeland L
Int Urogynecol J Pelvic Floor Dysfunct. 1996; 7(4):179-84.
PMID: 10895801
DOI: 10.1007/BF01907069.
Gynaecologic effects of tamoxifen.
Kuo D, Runowicz C
Med Oncol. 1995; 12(2):87-94.
PMID: 8535666
DOI: 10.1007/BF01676708.
A risk-benefit assessment of tamoxifen therapy.
Catherino W, Jordan V
Drug Saf. 1993; 8(5):381-97.
PMID: 8504018
DOI: 10.2165/00002018-199308050-00005.
The effect of tamoxifen on the endometrium.
Uziely B, Lewin A, Brufman G, Dorembus D, Mor-Yosef S
Breast Cancer Res Treat. 1993; 26(1):101-5.
PMID: 8400318
DOI: 10.1007/BF00682705.
Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.
Maenpaa J, Wiebe V, Koester S, Wurz G, Emshoff V, Seymour R
Cancer Chemother Pharmacol. 1993; 32(5):396-8.
PMID: 8339392
DOI: 10.1007/BF00735926.
Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.
Jordan V
Br J Pharmacol. 1993; 110(2):507-17.
PMID: 8242225
PMC: 2175926.
DOI: 10.1111/j.1476-5381.1993.tb13840.x.
What do we know and what don't we know about tamoxifen in the human uterus.
Friedl A, Jordan V
Breast Cancer Res Treat. 1994; 31(1):27-39.
PMID: 7981454
DOI: 10.1007/BF00689674.
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.
Powles T, Hardy J, Ashley S, Farrington G, Cosgrove D, Davey J
Br J Cancer. 1989; 60(1):126-31.
PMID: 2679843
PMC: 2247327.
DOI: 10.1038/bjc.1989.235.
Long-term adjuvant tamoxifen therapy for breast cancer.
Jordan V
Breast Cancer Res Treat. 1990; 15(3):125-36.
PMID: 2196941
DOI: 10.1007/BF01806350.
Can we prevent breast cancer?.
Baum M, Ziv Y, Colletta A
Br J Cancer. 1991; 64(2):205-7.
PMID: 1892745
PMC: 1977542.
DOI: 10.1038/bjc.1991.276.
